LTS:0RDU (Spain)
Business Description
Grifols SA
NAICS : 325412
Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
Compare
Compare
Traded in other countries / regions
GRF.Austria
•
G0FB.Germany
•
GRF.Spain
•
0RDU.UK
•
GRFS.USA
Description
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's bioscience business contributed 77% of sales in 2021. Grifols also has smaller segments including diagnostics, hospital supplies, and biosupplies. Diagnostics is now roughly 15% of revenue following the Novartis and Hologic deals.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.06 | |||||
| Equity-to-Asset | 0.3 | |||||
| Debt-to-Equity | 1.51 | |||||
| Debt-to-EBITDA | 34.97 | |||||
| Interest Coverage | 1.45 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 0.76 | |||||
| Beneish M-Score | -1.62 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 3.4 | |||||
| 3-Year EBITDA Growth Rate | -8.3 | |||||
| 3-Year EPS without NRI Growth Rate | -31.5 | |||||
| 3-Year FCF Growth Rate | -13 | |||||
| 3-Year Book Growth Rate | 9.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 39.67 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 4.29 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 32.23 | |||||
| 9-Day RSI | 32.23 | |||||
| 14-Day RSI | 33.26 | |||||
| 6-1 Month Momentum % | 10.19 | |||||
| 12-1 Month Momentum % | -22.48 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.68 | |||||
| Quick Ratio | 0.91 | |||||
| Cash Ratio | 0.34 | |||||
| Days Inventory | 922.62 | |||||
| Days Sales Outstanding | 122.9 | |||||
| Days Payable | 240.87 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Dividend Growth Rate | -3.4 | |||||
| 3-Year Average Share Buyback Ratio | 0.3 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 37.46 | |||||
| Operating Margin % | 12.01 | |||||
| Net Margin % | 5.86 | |||||
| ROE % | 1.59 | |||||
| ROA % | 0.48 | |||||
| ROIC % | 0.86 | |||||
| ROC (Joel Greenblatt) % | 4.96 | |||||
| ROCE % | 1.66 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 106 | |||||
| Forward PE Ratio | 27.25 | |||||
| PE Ratio without NRI | 106 | |||||
| Shiller PE Ratio | 12.64 | |||||
| PS Ratio | 3.77 | |||||
| PB Ratio | 1.48 | |||||
| Price-to-Free-Cash-Flow | 28.18 | |||||
| Price-to-Operating-Cash-Flow | 17.16 | |||||
| EV-to-EBIT | 54.2 | |||||
| EV-to-Forward-EBIT | 18.24 | |||||
| EV-to-EBITDA | 54.2 | |||||
| EV-to-Forward-EBITDA | 12.28 | |||||
| EV-to-Revenue | 9.6 | |||||
| EV-to-Forward-Revenue | 2.74 | |||||
| EV-to-FCF | 71.67 | |||||
| Price-to-Projected-FCF | 0.65 | |||||
| Price-to-Median-PS-Value | 1.57 | |||||
| Earnings Yield (Greenblatt) % | 1.85 | |||||
| Forward Rate of Return (Yacktman) % | 1.1 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1,542.899 | ||
| EPS (TTM) (€) | 0.13 | ||
| Beta | 0.28 | ||
| Volatility % | 41.04 | ||
| 14-Day RSI | 33.26 | ||
| 14-Day ATR (€) | 0.546236 | ||
| 20-Day SMA (€) | 14.7195 | ||
| 12-1 Month Momentum % | -22.48 | ||
| 52-Week Range (€) | 13.035 - 22.54 | ||
| Shares Outstanding (Mil) | 678.91 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Grifols SA Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||